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Polymorphisms of Nucleotide Excision Repair Genes
Predict Melanoma Survival
Chunying Li1,2, Ming Yin2, Li-E Wang2, Christopher I. Amos2,5, Dakai Zhu2,5, Jeffrey E. Lee3,
Jeffrey E. Gershenwald3, Elizabeth A. Grimm4 and Qingyi Wei2
Melanoma is the most highly malignant skin cancer, and nucleotide excision repair (NER) is involved in
melanoma susceptibility. In this analysis of 1,042 melanoma patients, we evaluated whether genetic variants of
NER genes may predict survival outcome of melanoma patients. We used genotyping data of 74 tagging single-
nucleotide polymorphisms (tagSNPs) in eight core NER genes from our genome-wide association study
(including two in XPA, 14 in XPC, three in XPE, four in ERCC1, 10 in ERCC2, eight in ERCC3, 14 in ERCC4, and
19 in ERCC5) and evaluated their associations with prognosis of melanoma patients. Using the Cox proportional
hazards model and Kaplan–Meier analysis, we found a predictive role of XPE rs28720291, ERCC5 rs4150314, XPC
rs2470458, and ERCC2 rs50871 SNPs in the prognosis of melanoma patients (rs28720291: AG vs. GG, adjusted
hazard ratio (adjHR)¼ 11.2, 95% confidence interval (CI) 3.04–40.9, P¼ 0.0003; rs4150314: AG vs. GG, adjHR¼ 4.76,
95% CI 1.09–20.8, P¼ 0.038; rs2470458: AA vs. AG/GG, adjHR¼ 2.11, 95% CI 1.03–4.33, P¼ 0.040; and rs50871: AA vs.
AC/CC adjHR¼ 2.27, 95% CI 1.18–4.35, P¼ 0.015). Patients with an increasing number of unfavorable genotypes
had markedly increased death risk. Genetic variants of NER genes, particularly XPE rs28720291, ERCC5 rs4150314,
XPC rs2470458, and ERCC2 rs50871, may independently or jointly modulate survival outcome of melanoma
patients. Because our results were based on a median follow-up of 3 years without multiple test corrections,
additional large prospective studies are needed to confirm our findings.
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INTRODUCTION
Melanoma is the most lethal skin cancer, ranking the sixth
most common cancer in the United States. There were
estimated 76,250 new melanoma cases, in addition to
55,560 melanoma in situ, in 2012 (Siegel et al., 2012).
Although surgery remains the mainstay treatment,
biochemotherapy and radiotherapy are also considered in an
attempt to improve local control and overall survival (OS).
Despite aggressive treatment, patients’ prognosis varies
substantially between individuals, with a 5-year survival rate
ranging from over 80% in early stages to o10% in patients
with distant metastasis (Buettner et al., 2005).
Some important tumor morphological and biological char-
acteristics are known to be associated with patients’ survival,
including primary tumor thickness, ulceration, mitotic activity,
lymph node infiltration, and distant metastasis (Spatz et al.,
2010). However, these histopathological features of primary
tumors do not provide sufficient information for assessing tumor
malignancy. For example, a subset of ‘‘thin’’ melanoma (tumor
thicknesso0.76 mm) can be lethal because of undetected
metastasis (Woods et al., 1983). Although the underlying
mechanisms are unclear, tumor genetic heterogeneity and inter-
actions among the host and tumor factors may be responsible
for rapid evolution and development of malignancies in these
patients. Some somatic mutations (e.g., BRAF and p16) are
commonly implicated in melanoma progression (Chin et al.,
2006), whereas an enhanced host’s immune system can
efficiently suppress cancer cell spreading, contributing to
prolonged survival (DiFronzo et al., 2002). Nevertheless, it is
possible that some other unknown genetic factors, by interacting
with the known clinicopathological factors, may modulate
survival outcomes of melanoma patients, thus uncovering
biomarker for patients’ long-term survival.
Previous epidemiologic studies have supported the notion that
DNA-damaging UV irradiation causes cutaneous melanoma
by inducing genetic abnormality (von Thaler et al., 2010).
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The well-studied nucleotide excision repair (NER) pathway
consists of at least 23 genes/proteins that act to remove
UV-induced DNA lesions. Several single-nucleotide
polymorphisms (SNPs) of the NER genes have been shown
to be associated with melanoma susceptibility (Li et al., 2006).
However, their influence on patients’ survival has not been
thoroughly investigated. In a recent study of eight
nonsynonymous SNPs of DNA repair genes (i.e., XPC
p.Ala499Val, XPC p.Lys939Gln, ERCC2 p.Lys751Gln, and
ERCC5 p.Asp1104His of NER; APEX1 p.Asp148Glu, XRCC1
p.Arg399Gln of base excision repair; and XRCC3
p.Thr241Met and NBS1 p.Glu185Gln of the homologous
recombination repair), only ERCC5 p.Asp1104His (rs17655)
and ERCC2 p.Lys751Gln (rs13181) were found to have an
effect on the prognosis of melanoma (Schrama et al., 2011),
suggesting that the NER genes may be involved in melanoma
outcomes, although genes involved in cell cycle checkpoint
are also found to be important (Kauffmann et al., 2008).
Here we report our results of an analysis of prognosis of
1,042 melanoma patients in association with 74 tagging SNPs
of the NER genes available to us in a previously published
genome-wide association study of melanoma (Amos et al.,
2011). In the present analysis, we evaluated the association
between these SNPs and survival and explored their
interactions with clinicopathological risk factors in
determining melanoma patients’ prognosis.
RESULTS
Patient characteristics
The analysis consisted of 1,042 patients with primary cuta-
neous melanoma (Table 1), who had available data from
questionnaire, genotyping, and survival. The patients were
aged between 18 and 84 years at diagnosis with a mean of
50.8 years and standard deviation of 13.1 years. There were
slightly more women than men (58.8 vs. 41.2%); 83.1% of the
patients had early-stage melanoma (in situ and stages I and II),
and 16.9% had later-stage melanoma (stages III and IV). We
also collected complete information on tumor morphology,
including primary tumor thickness, ulceration, metastasis to
local lymph nodes, mitotic rate (mitoses per mm2) of tumor
cells (because there was no association with mitotic rate by the
American Joint Committee on Cancer (AJCC) staging system of
mitosesX1/mm2 vs.o1/mm2, we used 3/mm2 as the cutoff as
shown in Table 1), anatomic site of the tumor, and patient
biological characteristics, including colors of the skin, hair, and
eyes, tanning ability after sun exposure, lifetime sunburns with
blistering, moles, and family history of skin cancer. The median
follow-up time was 35.7 months, during which 52 (5.0%) of
the 1,042 patients had died at the last follow-up.
To determine whether there was any confounding factor
influencing patients’ death or survival time, we performed Cox
proportional hazards regression analysis to assess the associa-
tion between OS and clinicopathological characteristics. In
the univariate analysis, older age, dark color of hair, freckling
in the sun as a child, advanced tumor stages, thick tumor,
presence of tumor ulceration, and increased primary tumor
mitotic rate were significant predictors for poor survival. When
all of these variables were included in a Cox proportional
hazards regression model for adjustment to calculate hazard
ratio (HR), only dark color of the skin (HR¼4.55), freckling in
the sun as a child (HR¼2.90), advanced AJCC stage
(HR¼ 5.60), and presence of tumor ulceration (HR¼2.72)
remained statistically significant predictors for poor survival
(Table 1).
Determination of melanoma survival prediction model
We performed the stepwise multivariate Cox proportional
hazards regression analysis to further screen for optimal
predictors of survival in melanoma patients, using covariates
listed in Table 1 and the 74 selected SNPs of the eight NER
core genes (i.e., two SNPs for XPA, 14 SNPs for XPC, three
SNPs for XPE/DDB1, four SNPs for ERCC1, 10 SNPs for
ERCC2/XD, eight SNPs for ERCC3/XPB, 14 SNPs for ERCC4/
XPF, and 19 SNPs for ERCC5/XPG). As shown in Table 2,
clinicopathological factors of age (p50 vs. 450), stage
(in situ/I/II vs. III/IV), ulceration (no vs. yes) and mitotic rate
(p3 vs. 43/mm2), and SNPs of rs28720291 (GG vs. AG),
rs4150314 (GG vs. AG), rs2470458 (AGþGG vs. AA), and
rs50871 (ACþCC vs. AA) were selected as the most signifi-
cant predictors of survival, of which covariates of late stages
(III/IV) (HR¼6.34; 95% confidence interval (CI) 3.11–11.9),
rs28720291 GG genotype (HR¼ 6.69; 95% CI 1.83–23.7),
and rs4150314 GG genotype (HR¼6.15; 95% CI 1.46–28.5),
were among the strongest predictors. Older age, ulceration,
increased mitotic rate, rs2470458 AG/GG genotypes, and
rs50871 AC/CC genotypes were of low or moderate risk
factors (1o HR o3).
NER genetic polymorphisms as independent survival risk factors
The initial stepwise Cox proportional hazards regression
analysis suggested four SNPs (XPE rs28720291, ERCC5
rs4150314, XPC rs2470458, and ERCC2 rs50871) as impor-
tant and independent predictors for survival of melanoma
patients. We further performed univariate and multivariate
Cox proportional hazards regression analyses to evaluate their
effects on risk of death or in the presence of other clinico-
pathological covariates. In the univariate analysis, XPE
rs28720291AG and ERCC2 rs50871AA genotypes were asso-
ciated with increased hazards of early death (AG vs. GG:
HR¼4.92, 95% CI 1.77–13.70, P¼ 0.002; and AA vs.
ACþCC: HR¼2.18, 95% CI 1.26–3.77, P¼0.005, respec-
tively). In the multivariate analyses performed with adjustment
for age, sex, tumor Breslow thickness, tumor stage, ulceration,
tumor cell mitotic rate, involvement of lymph nodes, and
tumor anatomic site, the four SNPs remained significantly
associated with survival outcome of melanoma patients (i.e.,
rs28720291: AG (no AA was observed) vs. GG 11.2, 95% CI
3.04–40.9, P¼0.0003; rs4150314: AG (no AA was observed)
vs. GG 4.76, 95% CI 1.09–20.8, P¼ 0.038; rs2470458:
AA vs. AGþGG 2.11, 95% CI 1.03–4.33, P¼0.040; and
rs50871: AA vs. ACþCC 2.27, 95% CI 1.18–4.35, P¼ 0.015)
(Table 3).
Survival of melanoma patients and combined genetic risk factors
To assess the joint effect of the four SNPs on patients’
prognosis, we combined their unfavorable genotypes (i.e.,
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Table 1. Associations of patient demographics and tumor-related characteristics with overall survival
Patient Death Univariate analysis Multivariate analysis2
Parameter1 No. % No. % HR 95% CI P-value HR 95% CI P-value
Age
p50 481 46.2 14 26.9 1.00 1.00
450 561 55.7 38 73.1 2.65 1.43–4.89 0.002 1.90 0.86–4.18 0.110
Sex
Female 613 58.8 36 69.2 1.00 1.00
Male 429 41.2 16 30.8 0.56 0.31–1.01 0.053 0.90 0.41–2.04 0.825
Skin color
Fair 938 90.1 47 9.6 1.00 1.00
Dark and brown 103 9.9 5 90.4 0.98 0.39–2.46 0.961 4.55 1.28–16.70 0.019
Hair color
Blond or red 355 34.1 10 19.2 1.00 1.00
Black or brown 686 65.9 42 80.8 2.13 1.08–4.35 0.030 0.86 0.37–2.00 0.735
Eye color
Not blue 604 58.0 29 55.8 1.00 1.00
Blue 437 42.0 23 44.2 1.08 0.63–1.87 0.781 0.62 0.30–1.27 0.192
Tanning ability after prolonged sun exposure
Good (high) 651 63.0 36 69.2 1.00 1.00
Poor (low) 382 37.0 16 30.8 0.77 0.43–1.39 0.39 1.26 0.58–2.77 0.560
Lifetime sunburns with blistering
0 302 29.0 18 35.3 1.00 1.00
X1 738 71.0 33 64.7 0.65 0.37–1.15 0.140 0.97 0.47–2.01 0.927
Freckling in the sun as a child
No 600 57.6 17 32.7 1.00 1.00
Yes 441 42.4 35 67.3 3.33 1.89–5.88 o0.0001 2.90 1.33–6.33 0.008
Moles
No 242 23.2 11 21.1 1.00 1.00
Yes 800 76.8 41 78.9 1.03 0.53–2.01 0.925 1.22 0.53–2.83 0.639
Dysplastic nevi
No 939 90.1 51 98.1 1.00 1.00
Yes 103 9.9 1 1.9 0.18 0.02–1.27 0.085 0.56 0.07–4.24 0.575
Family history of skin cancer
No 385 36.9 19 36.5 1.00 1.00
Yes 657 63.1 33 63.5 1.10 0.62–1.93 0.745 1.15 0.56–2.37 0.704
AJCC stages
In situ, I and II 866 83.1 24 46.1 1.00 1.00
III and IV 176 16.9 28 53.9 6.87 3.97–11.9 o0.0001 5.60 2.69–11.64 o0.0001
Primary tumor thickness
o1 mm 425 49.0 8 17.0 1.00 1.00
40.99 mm 443 51.0 39 83.0 5.17 2.42–11.1 o0.0001 2.14 0.72–6.35 0.169
Ulceration
No 846 87.2 28 59.6 1.00 1.00
Yes 124 12.8 19 40.3 5.71 3.19–10.2 o0.00001 2.72 1.28–5.78 0.0009
SLNB
No 333 32.1 13 25.5 1.00 1.00
Yes 705 67.9 38 74.5 1.31 0.69–2.49 0.417 0.44 0.19–1.03 0.058
Table 1 continued on following page
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XPE rs28720291AG, ERCC5 rs4150314AG, XPC rs247045
8AA, and ERCC2 rs50871AA genotypes). The frequencies of
patients with 0, 1, 2, and 3 unfavorable genotypes were 276,
566, 188, and 10, respectively; no patient had all four
unfavorable genotypes. Patients with an increasing number
of unfavorable genotypes had markedly increased risk of death
by over 30-fold (HR¼ 34.3; 95% CI 7.48–157.2; Po0.0001)
in patients with any three unfavorable genotypes, compared
with those without any unfavorable genotypes (Table 4 and
Figure 1). As there were only 10 patients carrying three
unfavorable genotypes, we next grouped all patients into a
low-risk group (patients with p1 unfavorable genotypes) and
a high-risk group (patients with two or three unfavorable
genotypes) for further stratified analysis (Table 4).
Stratification analysis between the unfavorable genotypes and
melanoma survival
We further performed stratified analysis to investigate whether
the combined effect of unfavorable genotypes on survival was
modified by some important clinicopathological factors in
Table 1. We found that only patients in the high-risk genotype
group, but not the low-risk genotype group, showed substan-
tially increased risk of death in the presence or absence of
concomitant clinicopathological risk factors (e.g., thick tumor,
involvement of lymph nodes, increased mitotic rate, advanced
AJCC tumor stages, presence of tumor ulceration, and tumor
site in face, head and neck), except for the subgroups of thin
tumor and without lymph node involvement (Figure 2).
DISCUSSION
In this relatively large melanoma patient cohort, we found that
some variants of the NER genes (e.g., XPE rs28720291, ERCC5
rs4150314, XPC rs2470458, and ERCC2 rs50871) may inde-
pendently or jointly modulate survival of melanoma patients.
These genetic variants, in combination with clinicopathologi-
cal factors, effectively predicted survival in subgroups of
melanoma patients.
Previous studies demonstrated that some clinicopatho-
logical characteristics were associated with the prognosis of
melanoma patients, such as hair color, history of childhood
freckling in the sun, tumor stage, and ulceration status
(Buettner et al., 2005). These results were also confirmed in
the current analysis. However, we were interested in finding
out some genetic variants of the NER genes that may have a
role in modulating patient survival. This is because NER is an
essential DNA repair mechanism that ensures genomic
integrity. There is evidence that genomic instability increases
not only in primary melanoma, compared with nevi, but also
in metastases, compared with primary tumors (Chin et al.,
2006). Hence, an increased NER capacity may reduce DNA
Table 1. Continued
Patient Death Univariate analysis Multivariate analysis2
Parameter1 No. % No. % HR 95% CI P-value HR 95% CI P-value
Mitotic rate (mitoses/mm2)
p3 589 78.6 20 47.6 1.00 1.00
43 160 21.4 22 52.4 4.70 2.56–8.63 o0.0001 1.54 0.74–3.23 0.251
Primary tumor anatomic site
Face, head, and neck 117 11.5 9 17.6 1.00 1.00
Trunk, extremities, and others 902 88.5 42 82.4 1.75 0.85–3.61 0.152 0.52 0.17–1.57 0.244
Abbreviations: CI, confidence interval; HR, hazard ratio; SLNB, sentinel lymph node biopsy.
1The numbers of subjects in some of the strata were less than the total number of subjects included in our study, because some subjects did not provide
complete information in their screening questionnaires.
2Multivariate Cox regression analyses were adjusted for all factors listed in Table 1.
Table 2. Predictors of overall survival in melanoma
patients obtained from stepwise multivariate cox
regression analysis of selected variables1
Selected variables P-value HR 95% CI
Age (p50 vs. 450) 0.003 1.05 1.01–1.07
Stage (in situ, I, II vs. III, IV) o0.0001 6.34 3.11–11.9
Ulceration (no vs. yes) 0.013 2.52 1.25–5.35
Mitotic rate (p3 vs. 43) 0.012 2.55 1.06–4.61
rs28720291 (GG vs. AG) 0.004 6.69 1.83–23.7
rs4150314 (GG vs. AG) 0.017 6.15 1.46–28.5
rs2470458 (AGþGG vs. AA) 0.025 2.42 1.08–4.76
rs50871 (ACþCC vs. AA) 0.020 2.23 1.18–4.50
Abbreviations: CI, confidence interval; HR, hazard ratio.
1Age, sex, tumor Breslow thickness, tumor stages, ulceration of the tumor,
tumor cell mitotic rate, involvement of lymph nodes, primary tumor
anatomic site, and the 74 selected SNPs of the eight NER core genes
(i.e., XPA (rs1800975 and rs2808667), XPC (rs1350344, rs2227999,
rs2228000, rs2228001, rs2470458, rs2607772, rs2733533, rs2733537,
rs3731062, rs3731125, rs3731127, rs3731146, rs3731149, and
rs3731151), XPE (rs2230356, rs4939513, and rs28720291), ERCC1
(rs11615, rs1007616, rs2298881, and rs3212955), ERCC2 (rs13181,
rs50871, rs171140, rs238406, rs238416, rs1052555, rs1618536,
rs1799786, rs1799787, and rs1799793), ERCC3 (rs1566823, rs1803541,
rs4150403, rs4150436, rs4150496, rs4150523, rs4662718, and
rs9282675), ERCC4 (rs254942, rs1799801, rs1800067, rs1800124,
rs2276464, rs2276465, rs2276466, rs3136146, rs3136166, rs3136187,
rs3136189, rs3136195, rs3743538, and rs16963255), and ERCC5
(rs17655, rs751402, rs873601, rs1047768, rs1047769, rs2227869,
rs2296147, rs2296148, rs4150260, rs4150275, rs4150314, rs4150330,
rs4150339, rs4150342, rs4150355, rs4150383, rs4771436, rs8002276,
and rs11069498)) genotypes were included in the stepwise multivariate
Cox proportional hazards regression analysis.
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mutations that may stimulate malignant progression and
metastasis. More interestingly, previously reported two
NER SNPs [ERCC5 p.Asp1104His (rs17655) and ERCC2
p.Lys751Gln (rs13181)] (Schrama et al., 2011) were
replicated in our current analysis, because they are tagged
by our selected tagging SNPs (ERCC5 rs4150314 and ERCC2
rs50871). However, we found that additional two NER SNPs
(XPE rs28720291 and XPC rs2470458) also independently
predicted the prognosis of melanoma. Therefore, our data
further support the notion that genetic variants in the NER
pathway may modulate clinical outcome of melanoma
patients.
NER uses a relatively small number of essential repair
proteins, including XPA, XPC, XPE/DDB1, ERCC1, ERCC2/
XPD, ERCC3/XPB, ERCC4/XPF, and ERCC5/XPG, to correct
bulky DNA damage induced by chemical carcinogens or UV
exposure. In brief, repair of the damaged DNA strand includes
making an incision at the 50 and 30 of the lesion, removing a
30-nucleotide section containing the damage, and ligating the
gap by pairing DNA synthesis (Sancar 1995). XPC-hHR23B is
an NER factor that detects DNA damage and recruits TFIIH
to the damaged site (Yokoi et al., 2000); then, proteins
encoded by XPA-G genes, the ERCC1-hHR23B-RPA
trimmers, and TFIIH are involved in the excision step
(de Boer and Hoeijmakers 1999). Two helicase subunits of
TFIIH (i.e., XPB and XPD), together with XPA, RPA, and XPG,
form a 30 base-pair bubble around the lesion for damage
verification and correct positioning of two endonucleases (i.e.,
XPG and XPF-ERCC1) before incision (Missura et al., 2001).
The incisions made by XPG and XPF-ERCC1 are at the double-
and single-stranded DNA border in the incision complex
(Sijbers et al., 1996). Observation of the mobility of various
NER proteins in living cells suggests that NER proceeds by
the sequential assembly of individual factors involved, rather
than through the action of a preassembled repairosome
(Houtsmuller et al., 1999).
Table 3. Association between selected NER genetic variants1 and overall survival of melanoma patients
Patient Death Univariate analysis Multivariate analysis2
Genotypes1 No. % No. % HR 95% CI P-value HR 95% CI P-value
XPE
rs28720291
GG 1,019 97.8 48 92.3 1.00 1.00
AG 23 2.2 4 7.7 4.92 1.77–13.7 0.002 11.2 3.04–40.9 0.0003
ERCC5
rs4150314
GG 1,021 98.2 50 96.1 1.00 1.00
AG 19 1.8 2 3.9 2.39 0.58–9.83 0.227 4.76 1.09–20.8 0.038
XPC
rs2470458
AA 646 62.1 37 71.1 1.00 1.00
AG 345 33.1 12 23.1 0.60 0.31–1.15 0.126 0.42 0.19–0.92 0.031
GG 50 4.8 3 5.8 1.06 0.33–3.43 0.927 0.89 0.21–3.78 0.879
AGþGG 395 37.9 15 28.9 0.66 0.36–1.20 0.175 0.47 0.23–0.97 0.040
AGþGG 395 37.9 15 28.9 1.00 1.00
AA 646 62.1 37 71.1 1.52 0.83–2.77 0.172 2.11 1.03–4.33 0.040
ERCC2
rs50871
AA 286 27.4 23 44.2 1.00 1.00
AC 529 50.8 18 34.6 0.41 0.22–0.76 0.005 0.45 0.22–0.90 0.024
CC 227 21.8 11 21.2 0.57 0.28–1.17 0.125 0.44 0.17–1.15 0.093
ACþCC 756 72.6 29 55.8 0.46 0.27–0.79 0.005 0.44 0.23–0.85 0.015
ACþCC 756 72.6 29 55.8 1.00 1.00
AA 286 27.4 23 44.2 2.18 1.26–3.77 0.005 2.27 1.18–4.35 0.015
Abbreviations: CI, confidence interval; HR, hazard ratio; NER, nucleotide excision repair.
1Only listed the four SNPs from the stepwise multivariate Cox proportional hazards regression analysis model shown in Table 2.
2Adjusted by age, sex, tumor Breslow thickness, tumor stage, ulceration of the tumor, tumor cell mitotic rate, involvement of lymph nodes, and primary tumor
anatomic site.
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Previous studies have extensively explored associations
between NER and melanoma susceptibility, but few investi-
gated the effects of NER on clinical outcomes of melanoma
patients. In a study of 90 stage IV melanoma patients, an
ERCC1-rs11615 SNP was found to be weakly associated with
OS (Liu et al., 2005). In another study of 244 melanoma
patients in Sweden, an ERCC2-rs13181 SNP was suggested to
be a prognostic factor for melanoma progression (Kertat et al.,
2008). More recently, both ERCC5-rs17655 and ERCC2-
rs13181 SNPs were found to be independent prognostic
factors in 742 melanoma patients (Schrama et al., 2011).
However, none of the above SNPs were replicated or in
linkage with the four positive SNPs (i.e., XPE-rs28720291,
ERCC5-rs4150314, XPC-rs2470458, and ERCC2-rs50871)
investigated in the present study. Several possible reasons
may explain the discrepancies: first, the studies by Liu et al.
and Kertat et al. were small sample-sized (90 cases and 244
cases, respectively), which could lead to chance findings or
miss some SNPs with mild effects because of a limited study
power; second, the majority of melanoma patients in these
two studies had late-stage tumors (stages III/IV), whereas a
large proportion of patients in our analysis and the study by
Schrama et al. had early-stage tumors (866/1044 and 652/742,
respectively).
Despite these discrepancies, there was some consistency
among these published studies and ours. If excluding the
most small-sized study by Liu et al., it appears that there are
increasing levels of significance as well as increasing number
of genes as the study patient population size increases, and the
significant SNPs/genes identified in previous small-sized study
could be confirmed by later larger-sized studies (ERCC2 in
244 patients, ERCC2 and ERCC5 in 742 patients, and ERCC2,
ERCC5, XPC, and XPE in 1,042 patients). As SNPs may alter
the related gene’s function, our analysis, together with
previous studies, suggested that the four genes, ERCC2/XPD,
ERCC5/ XPG, XPC, and XPE/ERCC3, may have important roles
in modulating melanoma patients’ survival.
Although the effect of a single SNP on cancer risk or clinical
outcomes, if any, may be limited, the combined effect of
several SNPs in the same or different genes could be more
Table 4. Association between combined NER variants and overall survival of melanoma patients
Patient Death Univariate analysis Multivariate analysis2
No. of variant genotypes1 No. % No. % HR 95% CI P-value HR 95% CI P-value
No. of variant genotypes1 0.0005 o0.00001
0 276 26.5 9 17.3 1.00 1.00
1 566 54.4 23 44.2 1.28 0.59–2.78 0.525 1.26 0.51–3.10 0.061
2 188 18.1 17 32.7 2.94 1.31–6.59 0.009 3.90 1.50–10.1 0.005
3 10 1.0 3 5.7 17.8 4.77–66.3 o0.0001 34.3 7.48–157.2 o0.0001
Ptrend o0.0001
Combined group
0–1 844 81.0 32 61.5 1.00 1.00
2–3 198 19.0 20 38.5 2.10 1.42–3.12 0.0002 4..01 2.04–7.86 o0.0001
Abbreviations: CI, confidence interval; HR, hazard ratio.
1rs28720291AG, rs4150314AG, rs2470458AA, and rs50871AA.
2Multivariate Cox proportional Hazards regression analysis with adjustment for age, sex, tumor Breslow thickness, tumor stage, ulceration of the tumor, tumor
cell mitotic rate, involvement of lymph nodes, and primary tumor anatomic site.
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Figure 1. Kaplan–Meier overall survival analysis for patients with primary melanoma by combined nucleotide excision repair (NER) genotypes (i.e., rs28720291
GG, rs4150314 GG, rs2470458 AGþGG, and rs50871 ACþCC). (a) By 0, 1, 2, and 3 NER variant genotypes (Po0.0001); and (b) by 0–1 and 2–3 NER variant
genotypes (P¼0.0001).
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significant. In the present analysis, we were also interested in
whether there was an additive/synergistic effect in the associa-
tion of the four SNPs (XPE-rs28720291, ERCC5-rs4150314,
XPC-rs2470458, and ERCC2-rs50871) with melanoma survi-
val. Indeed, patients with two or three unfavorable genotypes
showed markedly increased risk of death, compared with
those with none or one unfavorable genotype. This is
biologically plausible, because multiple variants may be more
likely to have a substantial joint effect on the DNA repair
capacity phenotype.
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Figure 2. Kaplan–Meier overall survival curves for patients with primary melanoma of 0–1 and 2–3 nucleotide excision repair (NER) variant genotypes
(i.e., rs28720291 GG, rs4150314 GG, rs2470458 AGþGG, and rs50871 ACþCC) by tumor-related characters. (a, b) By tumor Breslow thickness (Po0.0001);
(c, d) by sentinel lymph node biopsy (SLNB) (Po0.0001); (e, f) by mitotic rate (Po0.0001); (g, h) by American Joint Committee on Cancer stages (Po0.0001);
(i, j) by ulceration (Po0.0001); and (k, l) by primary tumor anatomic site (Po0.0001).
C Li et al.
NER Variants Predict Melanoma Survival
www.jidonline.org 1819
Through stratified analyses, we found that the genotype–
survival association was the most pronounced in the presence
of clinicopathological risk factors, suggesting that suboptimal
repair of DNA damage induced externally (UV exposure) or
internally (free radicals from metabolism) could aggregate the
existing genomic instability of a fast-growing melanoma,
promoting melanoma development and progression in the
high-risk populations. As these high-risk patients comprised
20.0% (198 out of 1,042) of all the study subjects, our analysis
identified a significant proportion of melanoma patients (such
as those with unfavorable genotypes) that may require close
clinical surveillance or alternative treatment to improve their
survival.
The current analysis has some limitations. First, as we used
a tagging SNP approach, we were not able to explore the
mechanism by which the studied genetic polymorphisms
influence melanoma patients’ survival. Although the four
identified SNPs and their tagged SNPs (LD X0.8) may have
potential biological functions as predicted by software tools
(http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm), none of
them have been reported or investigated as functional SNPs
in the literature. Only four SNPs tagged by XPC-rs2470458
were found to be associated with the risk of bladder cancer
(rs2228000, rs2470352, and rs2470458) and lung cancer
(rs2229090) in previous association studies (Shen et al.,
2005; Stern et al., 2009). Further functional studies of these
SNPs are required. Second, there were only 52 deaths out of
1,042 patients at our last follow-up at a median of nearly 3
years. Therefore, the current study is, to a large extent, an
interim survival analysis. We will report updated results after
we have a longer follow-up time. Third, we did not adjust for
multiple tests, simply because this was an exploratory study
with a limited study power. We plan to confirm current
findings in our ongoing prospective expansion studies in more
stringent conditions with a larger study population. Fourth, as
treatment of melanoma, advanced melanoma in particular,
has not been standardized, patients included in the current
analysis who developed advanced melanoma may have
received a wide variety of systemic therapies, often
sequentially. The systemic therapies available for the cohort
of patients included in our analysis would only have been
expected to be modestly effective in a minority of melanoma
patients (the study period ended in 2008; vemurafenib was
approved by the FDA for the treatment of advanced
melanoma in 2011). Because of the variety of treatments
administered (often multiple types of treatments to the same
patient) and their very modest anticipated effect on OS, we did
not evaluate the potential role of these therapies in the
outcomes of the patients, or their potential relationship to
the polymorphisms identified. Although evaluation of the
association between the polymorphisms investigated and
response to a variety of melanoma systemic therapies is
important, such an evaluation is beyond the scope of the
current analysis.
In summary, we identified four SNPs of the NER genes
(i.e., XPE rs28720291, ERCC5 rs4150314, XPC rs2470458,
and ERCC2 rs50871) that may have independent or joint
effects on survival of melanoma patients. These findings, once
validated in future prospective studies with large sample sizes
and better study designs, will provide some promising gui-
dance for clinical management and tailored or personalized
therapeutics in treating melanoma patients.
MATERIALS AND METHODS
Study populations
Patients were accrued for an ongoing, hospital-based, case–control
study of epidemiologic and genetic risk factors for melanoma. A total
of 1,042 histologically confirmed patients with melanoma in situ and
stage I to stage IV were enrolled between January 2000 and
September 2008. Patients were enrolled into the study regardless of
age, sex, or disease stage. On entry into the study, each patient had a
personal interview to elicit lifestyle factors, using a standardized
questionnaire. Each patient also had a 30-ml sample of blood drawn
for various biomarker studies, including genotyping. All patients were
enrolled and diagnosed with staging system defined by the AJCC at
The University of Texas MD Anderson Cancer Center, Houston, TX.
Specifically, melanoma patients with melanoma in situ, stage I/II
(primary tumor without evidence of regional or distant metastasis at
diagnosis), stage III (locoregional disease, including in transit, satellite,
and/or regional lymph node metastasis at diagnosis), and stage IV
(distant metastasis at diagnosis) were classified according to the AJCC
melanoma staging system (Balch et al., 2009). For patients with stage
I/II disease, staging elements included Breslow primary tumor
thickness, presence or absence of primary tumor ulceration, and
mitotic rate (i.e., number of mitoses per square millimeter using
dermal hotspot approach). All patients gave a written informed
consent, and the protocol was approved by the MD. Anderson
Cancer Center Institutional Review Board. Patients were evaluated,
staged, treated, and followed using the standard guidelines, including
the use of sentinel lymph node biopsy for high-risk primary
melanoma (Gershenwald and Ross, 2011). Patients with high-risk
local-regional, and those with recurrent and metastatic melanoma,
received a variety of protocol-based and off-protocol systemic
therapies, on the basis of standard guidelines, physician
recommendations, and patient preferences. The study protocol and
informed consent were in compliance with Declaration of Helsinki
Principles.
Polymorphism selection and genotyping
Genomic DNA was extracted from the buffy coat fraction of each
blood sample by using a Blood Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. DNA purity and con-
centrations were determined by spectrophotometric measurement of
absorbance at 260 and 280 nm by a UV spectrophotometer (Nano
Drop Technologies, Wilmington, DE). The SNPs were genotyped
using the Illumina HumanOmni1-Quad_v1-0_B array and were
called using the BeadStudio algorithm, at the John Hopkins University
Center for Inherited Disease Research. In this analysis, we selected
the available 74 tagging SNPs in eight core NER genes, including XPA
(rs1800975 and rs2808667), XPC (rs1350344, rs2227999, rs2228000,
rs2228001, rs2470458, rs2607772, rs2733533, rs2733537,
rs3731062, rs3731125, rs3731127, rs3731146, rs3731149, and
rs3731151), XPE (rs2230356, rs4939513, and rs28720291), ERCC1
(rs11615, rs1007616, rs2298881, and rs3212955), ERCC2 (rs13181,
rs50871, rs171140, rs238406, rs238416, rs1052555, rs1618536,
rs1799786, rs1799787, and rs1799793), ERCC3 (rs1566823,
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rs1803541, rs4150403, rs4150436, rs4150496, rs4150523,
rs4662718, and rs9282675), ERCC4 (rs254942, rs1799801,
rs1800067, rs1800124, rs2276464, rs2276465, rs2276466,
rs3136146, rs3136166, rs3136187, rs3136189, rs3136195,
rs3743538, and rs16963255), and ERCC5 (rs17655, rs751402,
rs873601, rs1047768, rs1047769, rs2227869, rs2296147,
rs2296148, rs4150260, rs4150275, rs4150314, rs4150330,
rs4150339, rs4150342, rs4150355, rs4150383, rs4771436,
rs8002276, and rs11069498). Any SNP with a call rate lower than
95% was excluded from further analysis.
Statistical analysis
We used the Cox proportional hazards regression model to evaluate
the effect of genotypes and clinicopathological variables on OS,
calculated as hazard ratios (HRs) with their corresponding 95% CIs.
We performed a stepwise conditional logistic regression analysis to
explore the best model to predict the survival outcome. The survival
time was calculated from the first day of diagnosis until the date of
event or the last-known follow-up. All HRs were adjusted for age, sex,
tumor stage, tumor Breslow thickness, ulceration of tumor, tumor cell
mitotic rate, involvement of lymph node, and primary tumor
anatomic site. Kaplan–Meier analysis was used to evaluate the effects
of clinicopathological and genetic variables on the cumulative pro-
bability of OS. All reported P-values were two-sided, and Po0.05
was considered to indicate statistical significance. All analyses were
performed using SAS software (version 9.1; SAS Institute, Cary, NC).
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